Peptides are emerging as drugs, gene delivery carriers, and diagnostic tools for genetic disorders — an underexplored therapeutic frontier with growing clinical potential.
3 roles for peptides in genetic diseasePeptides can act as direct therapeutics, deliver gene therapy payloads to target cells, and serve as biomarkers for mutation detection — a uniquely versatile platform for genetic disorders
What the researchers found
Peptides are emerging as versatile tools for treating genetic disorders through multiple mechanisms beyond just acting as drugs. The review identifies three key roles for peptides in this space:
1. **Direct therapeutics**: A limited but growing number of peptide-based drugs treat genetic disorders, with several more in clinical trials. Most current therapies provide symptomatic relief rather than addressing the underlying genetic defect.
2. **Gene delivery carriers**: Peptides can serve as vehicles to deliver gene therapy payloads (corrective DNA or RNA) to target cells, overcoming delivery challenges that have limited gene therapy.
3. **Diagnostic tools**: Peptide-based biomarkers can detect specific mutations, and peptide vaccines are being explored as treatments for certain genetic conditions.
The review maps the mechanistic underpinnings of various genetic disorders and identifies where peptide-based approaches could be most beneficial.
Why it matters
Genetic disorders affect millions of people worldwide with limited treatment options — most therapies only manage symptoms. The peptide field has largely focused on metabolic, cardiovascular, and oncology indications, but this review highlights an underexplored frontier: using peptide versatility (as drugs, carriers, and diagnostics) to address genetic diseases. As gene therapy advances, peptide-based delivery systems could solve the critical 'last mile' delivery problem that has limited many gene therapies.
The numbers in context
Limited number of approved peptide drugs for GDs · Several candidates in clinical trials · 3 peptide roles: therapeutics, gene carriers, diagnostics · Multiple genetic disorder mechanisms reviewed
How the study worked
This is a narrative review published in Drug Discovery Today that surveys the landscape of peptide-based approaches to genetic disorders. The authors examine the underlying biology of various genetic diseases, current peptide drugs and clinical candidates, and emerging applications of peptides as gene delivery vehicles and diagnostic tools.
Who was studied
Review covering peptide-based approaches across multiple genetic disorders
What this study cannot tell us
As a narrative review, it doesn't use systematic methodology or quantitatively assess evidence. The peptide-based genetic disorder space is relatively early-stage, so much of the review covers preclinical and conceptual work rather than proven therapies. The breadth of genetic disorders covered means depth on any single condition is limited.
How to read the evidence
This is a narrative review from a respected drug discovery journal. It provides a useful landscape overview but covers a field that is largely preclinical. Most described applications are conceptual or in early development, with only a limited number of approved peptide drugs for genetic disorders.
When this study was published
Published in 2024, this review captures the current state of a rapidly evolving field. The convergence of peptide science with gene therapy and precision medicine means the landscape described may advance quickly.
The bigger picture
The intersection of peptide science and genetic medicine is an emerging frontier. As gene therapy becomes more practical, the delivery challenge — getting the corrective gene to the right cells — has become the primary bottleneck. Peptides offer a potential solution: cell-penetrating peptides, targeting peptides, and peptide-nucleic acid conjugates could overcome the delivery barriers that have limited gene therapy's reach. This review positions peptides as key enablers of the next generation of genetic treatments.
Questions still open
- Which genetic disorders are most amenable to peptide-based therapeutic approaches versus gene therapy or small molecules?
- Can peptide-based gene delivery systems compete with viral vectors in efficiency while offering better safety profiles?
- Will peptide vaccines for genetic disorders reach clinical validation, or will gene editing approaches like CRISPR make them obsolete?
Common questions
Can peptides treat genetic disorders?
How are peptides used to deliver gene therapy?
Read the original research
Peptide-based therapeutics targeting genetic disorders.
Drug discovery today, 29(12), 104209
Citation
Subramanian, Shweta; Jain, Meenakshi; Misra, Rajkumar; Jain, Rahul. (2024). Peptide-based therapeutics targeting genetic disorders.. Drug discovery today, 29(12), 104209. https://doi.org/10.1016/j.drudis.2024.104209